Prediction of survival and outcomes with depth of response at 6 months in metastatic non-small-cell lung cancer patients treated with chemotherapy and immunotherapy combination: SPORE trial.

Fiche publication

Date publication

janvier 2026

Journal

ESMO open

Auteurs

Membres identifiés du Cancéropôle Est :
Dr SCHOTT Roland , Dr SOMME Laura

Tous les auteurs :
Moinard-Butot F, Barbe-Richaud JB, Lasvergnas J, Ancel J, Justeau G, Le Floch H, Somme L, Chouaid C, Bylicki O, Schott R

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/41616390

Résumé

Metastatic non-small-cell lung carcinoma (mNSCLC) first-line therapy is based on the combination of chemotherapy with immune checkpoint inhibitors (ICIs). Early assessment of long-term outcomes may be crucial to guide clinician's decisions. Whether radiological depth of response (DpR) could be a surrogate of survival remains unsolved.